BIGMAR GETS BRAZILIAN APPROVAL TO MARKET FLUOROURACIL.
A potent anticancer agent, 5-fluorouracil is used in combination with other drugs to treat ovarian and breast cancer. The ANVS action marks the first oncological product approval received by Bigmar in Brazil.
"We intend to market 5-fluorouracil under the Bigmar label," said John G. Tramontana, chairman and chief executive officer. "We anticipate receiving ANVS approvals for additional oncology products during 2000.
"The anticancer market in Brazil is growing at a substantial rate," Tramontana added. "We hope to capture a material share of the generic business in the near term."
Bigmar is a manufacturer of generic pharmaceutical oncology products and intravenous infusion solutions, which it manufactures at its state-of-the-art facilities in Switzerland. The company markets its products through partnerships of pharmaceutical distributors in Europe and the United States and focuses on off-patent oncological pharmaceuticals. For more information, visit the company's Web site, www.bgmr.com or call 740/966-5800.
|Printer friendly Cite/link Email Feedback|
|Comment:||BIGMAR GETS BRAZILIAN APPROVAL TO MARKET FLUOROURACIL.|
|Article Type:||Brief Article|
|Date:||Jul 1, 2000|
|Previous Article:||BABIES TO BE SCREENED FOR DIABETES RISK GENES IN SWEDEN.|
|Next Article:||NATIONAL RESEARCH COUNCIL OF CANADA ACCEPTS AUTOMATED LAB.|